
Congresses
Congress Materials
Access abstracts, posters, and presentations presented at the following congresses
December 2023
American Society of Hematology (ASH)
American Society of Hematology (ASH)
December 2023 (San Diego, California, USA)
Abstracts
A phase 4, observational study evaluating the efficacy and safety of the Bruton tyrosine kinase inhibitor (BTKi) zanubrutinib in patients with Waldenström macroglobulinemia (WM)
Acquired mutations in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) that progressed in the ALPINE study
Broad superiority of zanubrutinib (zanu) over bendamustine + rituximab (BR) across multiple high-risk factors: Biomarker subgroup analysis in the phase 3 SEQUOIA study in patients with treatment-naive (TN) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without del(17p)
Clinical outcomes in patients with Waldenström macroglobulinemia (WM) receiving ibrutinib on the phase 3 ASPEN study ≥1 year after transitioning to zanubrutinib
Combination treatment with sonrotoclax (BGB-11417), a second-generation BCL2 inhibitor, and zanubrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is well tolerated and achieves deep responses in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (TN-CLL/SLL): data from an ongoing phase 1/2 study
Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL)
First results from a phase 1, first-in-human study of Bruton's tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) B-cell malignancies
Genomic landscape of ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies treated with zanubrutinib in a phase 2 study
Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma (R/R FL) treated with zanubrutinib+ obinutuzumab versus obinutuzumab monotherapy: the ROSEWOOD trial
Impact of real-world treatment sequencing patterns on time to next treatment among patients with chronic lymphocytic leukemia in the United States
Monotherapy with second-generation BCL2 inhibitor sonrotoclax (BGB-11417) is well tolerated with high response rates in patients with relapsed/refractory marginal zone lymphoma: data from an ongoing phase 1 study
Number needed to treat analyses of zanubrutinib in relapsed/refractory chronic lymphocytic leukemia
Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns among patients with chronic or small lymphocytic leukemia (CLL/SLL) in US community oncology practices
Real-world evaluation of treatment discontinuation and healthcare resource utilization in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
Real-world patterns of care and financial burden of patients with follicular lymphoma in the United States
Real-world switching pattern, persistence, and associated healthcare resource utilization of Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma in the United States
Recent patterns of care with BTK inhibitors and distribution of social determinants of health among patients with CLL/SLL in the US community setting
Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison
Sonrotoclax (BGB-11417) in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma with t(11;14): safety, efficacy, and determination of recommended phase 2 dose
Tislelizumab, an anti-PD1 antibody, in patients with relapsed/refractory classical Hodgkin lymphoma in TIRHOL BGB-A317-210: a prospective multicenter Lysa phase 2 study conducted in Western countries
Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia
Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies
Zanubrutinib vs FCR in fit treatment-naive patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison
November 2023
Australasian Gastro-Intestinal Trials Group (AGITG)
Australasian Gastro-Intestinal Trials Group (AGITG)
November 2023 (Christchurch, New Zealand)
November 2023
International Society for Pharmacoeconomics and Outcomes Research - Europe (ISPOR-EU)
International Society for Pharmacoeconomics and Outcomes Research - Europe (ISPOR-EU)
November 2023 (Copenhagen, Denmark)
Posters
Bruton tyrosine kinase inhibitor (BTKi) monotherapy for the treatment of ‘high-risk’ patients with previously untreated chronic lymphocytic leukemia (CLL): a systematic literature review (SLR)
Cost-minimization analysis (CMA) of Bruton tyrosine kinase inhibitors (BTKis) in adults with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
Cost-utility analysis (CUA) in chronic lymphocytic leukemia (CLL): Is COVID-19’s impact on national life tables important to consider?
Global clinical, economic, health-related quality of life burden, and treatment outcomes in follicular lymphoma: a systematic review
Incidence, prevalence, and clinical characteristics of patients with chronic lymphocytic leukemia (CLL) in Spain: natural language processing (NLP) analysis of electronic health records (EHRs)
Psychometric validation of QLQ-OES18 in 2L esophageal squamous cell cancer (ESCC) patients treated with tislelizumab versus chemotherapy
Q-TWiST analysis is back in the game in oncology clinical trial analysis: a recent trend
Quality of life and economic burden of advanced non-small cell lung cancer in medium and small markets (MED&SM): a systematic literature review
Targeted treatments for patients with relapsed and/or refractory (R/R) chronic lymphocytic leukemia (CLL): a systematic literature review (SLR) of randomized clinical trials (RCTs)
The disease and economic burden of hepatocellular carcinoma in Australia
Treatment patterns and adverse events (AEs) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in France, Italy, and the United Kingdom (UK)
Unmet needs and evidence gaps in relapsed/refractory marginal zone lymphoma: findings from a systematic literature review
Abstracts
Bruton tyrosine kinase inhibitor (BTKi) monotherapy for the treatment of ‘high-risk’ patients with previously untreated chronic lymphocytic leukemia (CLL): a systematic literature review (SLR)
Cost-minimization analysis (CMA) of Bruton tyrosine kinase inhibitors (BTKis) in adults with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
Cost-utility analysis (CUA) in chronic lymphocytic leukemia (CLL): Is COVID-19’s impact on national life tables important to consider?
Global clinical, economic, health-related quality of life burden, and treatment outcomes in follicular lymphoma: a systematic review
Incidence, prevalence, and clinical characteristics of patients with chronic lymphocytic leukemia (CLL) in Spain: natural language processing (NLP) analysis of electronic health records (EHRs)
Psychometric validation of QLQ-OES18 in 2L esophageal squamous cell cancer (ESCC) patients treated with tislelizumab versus chemotherapy
Q-TWiST analysis is back in the game in oncology clinical trial analysis: a recent trend
Quality of life and economic burden of advanced non-small cell lung cancer in medium and small markets (MED&SM): a systematic literature review
Targeted treatments for patients with relapsed and/or refractory (R/R) chronic lymphocytic leukemia (CLL): a systematic literature review (SLR) of randomized clinical trials (RCTs)
The disease and economic burden of hepatocellular carcinoma in Australia
Treatment patterns and adverse events (AEs) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in France, Italy, and the United Kingdom (UK)
Unmet needs and evidence gaps in relapsed/refractory marginal zone lymphoma: findings from a systematic literature review
November 2023
Portuguese Society of Hematology (SPH)
Portuguese Society of Hematology (SPH)
November 2023 (Viseu, Portugal)
Posters
Abstracts
November 2023
BLOOD Annual Scientific Meeting (BLOOD)
BLOOD Annual Scientific Meeting (BLOOD)
November 2023 (Melbourne, Australia)
Presentations
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with NHL, or Waldenström macroglobulinemia (WM): preliminary data
Incidence, prevalence, and mortality of Waldenström macroglobulinemia (WM) in Australia
Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA (BGB-3111-214) trial
Posters
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data
Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Health-related quality of life (HRQOL) in patients with Waldenström macroglobulinemia (WM) treated with zanubrutinib or ibrutinib: results from long-term follow-up of the phase 3 ASPEN trial
Incidence, prevalence, and mortality of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Australia
Zanubrutinib demonstrates superior progression-free survival (PFS) vs ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): final analysis of randomized phase 3 ALPINE study
Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQOL)
Abstracts
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with NHL, or Waldenström macroglobulinemia (WM): preliminary data
Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Health-related quality of life (HRQOL) in patients with Waldenström macroglobulinemia (WM) treated with zanubrutinib or ibrutinib: results from long-term follow-up of the phase 3 ASPEN trial
Incidence, prevalence, and mortality of Waldenström macroglobulinemia (WM) in Australia
Incidence, prevalence, and mortality of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Australia
Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA (BGB-3111-214) trial
Zanubrutinib demonstrates superior progression-free survival (PFS) vs ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): final analysis of randomized phase 3 ALPINE study
Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQOL)
November 2023
American Society of Nephrology Kidney Week (ASN Kidney Week)
American Society of Nephrology Kidney Week (ASN Kidney Week)
November 2023 (Philadelphia, Pennsylvania, USA)
November 2023
Annual Meeting of the Japan Lung Cancer Society (JLCS)
Annual Meeting of the Japan Lung Cancer Society (JLCS)
November 2023 (Chiba, Japan)
October 2023
Spanish Society of Hematology and Hemotherapy (SEHH)
Spanish Society of Hematology and Hemotherapy (SEHH)
October 2023 (Sevilla, Spain)
Presentations
Zanubrutinib (ZANU) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study
Zanubrutinib (zanu) in relation to ibrutinib (ibr) improves PFS in patients with refractory/recurrent (R/R) CLL: final analysis of the ALPINE study
Posters
Evaluation of treatment and safety patterns in patients with chronic lymphocytic leukemia (CLL) using natural language processing (NLP): perspective of a multicenter observational study in Spain
Health-related quality of life in patients (Pts) with Waldenström macroglobulinemia (WM) treated with zanubrutinib (ZANU) vs ibrutinib (IBR): phase 3 ASPEN trial long-term follow-up results
Phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib for CLL/SLL: preliminary data
Phase 1 study with the novel Bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib for NHL or Waldenström macroglobulinemia (WM): preliminary data
Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
Abstracts
Evaluation of treatment and safety patterns in patients with chronic lymphocytic leukemia (CLL) using natural language processing (NLP): perspective of a multicenter observational study in Spain
Health-related quality of life in patients (pts) with Waldenström macroglobulinemia (WM) treated with zanubrutinib (zanu) vs ibrutinib (ibr): phase 3 ASPEN trial long-term follow-up results
MAHOGANY: phase III trial of zanubrutinib (Z) plus anti-CD20 antibodies against lenalidomide plus rituximab (L+R) in patients (pts.) with relapsed/refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL) (R/R)
Phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib for CLL/SLL: preliminary data
Phase 1 study with the novel Bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib for NHL or Waldenström macroglobulinemia (WM): preliminary data
Zanubrutinib (ZANU) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study
Zanubrutinib (zanu) in relation to ibrutinib (ibr) improves PFS in patients with refractory/recurrent (R/R) CLL: final analysis of the ALPINE study
Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
October 2023
Italian Society of Hematology (SIE)
Italian Society of Hematology (SIE)
October 2023 (Rome, Italy)
Presentations
A phase 1 study with the novel B-cell lymphoma 2 inhibitor sonrotoclax (BGB-11417) as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with CLL/SLL: preliminary data
Updated safety and efficacy results of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib
Zanubrutinib (zanu) demonstrates superior progression-free survival vs ibrutinib for treatment of R/R CLL/SLL: final analysis of phase 3 ALPINE study
Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study
Zanubrutinib + obinutuzumab vs obinutuzumab in patients with R/R FL: updated analysis of the ROSEWOOD study
Posters
A phase 1 study with the novel B-cell lymphoma 2 inhibitor sonrotoclax (BGB-11417) as monotherapy or in combination with zanubrutinib in patients with non-Hodgkin lymphoma or Waldenström macroglobulinemia: preliminary data
Health-related quality of life in patients (pts) with Waldenström macroglobulinemia (WM) treated with zanubrutinib (zanu) vs ibrutinib (ibr): results from the phase 3 ASPEN trial long-term follow-up
Long-term efficacy and safety of zanubrutinib (zanu) in patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (R/R MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients (pts) with relapsed or refractory follicular or marginal zone lymphoma
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: impact on health-related quality of life
Abstracts
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
A phase 1 study with the novel B-cell lymphoma 2 (BCL-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with CLL/SLL: preliminary data
A phase 1 study with the novel B-cell lymphoma 2 (BCL-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with non-Hodgkin lymphoma (NHL) or Waldenström macroglobulinemia (WM): preliminary data
Health-related quality of life in patients (pts) with Waldenström macroglobulinemia (WM) treated with zanubrutinib (zanu) vs ibrutinib (ibr): results from the phase 3 ASPEN trial long-term follow-up
Long-term efficacy and safety of zanubrutinib (zanu) in patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients (pts) with relapsed or refractory (R/R) follicular or marginal zone lymphoma (FL or MZL)
Updated safety and efficacy results of zanubrutinib (zanu) in patients with B-cell malignancies who are intolerant of ibrutinib (ibr) and/or acalabrutinib (aca)
Zanubrutinib (zanu) demonstrates superior progression-free survival (PFS) vs ibrutinib (ibr) for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): final analysis of phase 3 ALPINE study
Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study
Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
October 2023
Florida Society of Clinical Oncology Fall Session (FLASCO)
Florida Society of Clinical Oncology Fall Session (FLASCO)
October 2023 (Orlando, Florida, USA)
October 2023
European Society For Medical Oncology (ESMO)
European Society For Medical Oncology (ESMO)
October 2023 (Madrid, Spain)
Presentations
AdvanTIG-203: phase 2 randomized, multicenter study of ociperlimab (oci) + tislelizumab (tis) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PDL1) positivity
AdvanTIG-202: Phase 2 randomized, multicenter, open-label study of tislelizumab (tis) with or without ociperlimab (oci) in patients (pts) with previously treated recurrent/metastatic (r/m) cervical cancer (CC)
AdvanTIG-206: phase 2 randomized open-label study of ociperlimab (oci) + tislelizumab (tis) + BAT1706 (bevacizumab biosimilar) Versus tis + BAT1706 in Patients (pts) with advanced hepatocellular carcinoma (HCC)
Pathological response to neoadjuvant tislelizumab plus platinum-doublet chemotherapy in resectable stage II-IIIa NSCLC patients in the phase 3 RATIONALE-315 trial
View Summary of Presentation in Plain Language
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: final analysis results of the RATIONALE-305 study
View Summary of Presentation in Plain Language
Posters
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (oci) + tislelizumab (tis) with chemotherapy (ct) in patients (pts) with metastatic esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC)
Long-term follow-up of a Phase 2 Study of tislelizumab (tis) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors
Phase (Ph) 1/2 study of sitravatinib (sitra) alone or with tislelizumab (tis) in advanced hepatocellular carcinoma (HCC) and gastric/gastroesophageal junction cancer (GC/GEJC)
Randomized, global, Phase 3 study of tislelizumab (tis) + chemotherapy (chemo) vs placebo (pbo) + chemo as first-line (1l) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306
Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): updated results from a phase 1b/2 study
Abstracts
AdvanTIG-203: phase 2 randomized, multicenter study of ociperlimab (oci) + tislelizumab (tis) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PDL1) positivity
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (oci) + tislelizumab (tis) with chemotherapy (ct) in patients (pts) with metastatic esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC)
AdvanTIG-202: phase 2 randomized, multicenter, open-label study of tislelizumab (tis) with or without ociperlimab (oci) in patients (pts) with previously treated recurrent/metastatic (r/m) cervical cancer (CC)
AdvanTIG-206: phase 2 randomized open-label study of ociperlimab (oci) + tislelizumab (tis) + BAT1706 (bevacizumab biosimilar) Versus tis + BAT1706 in Patients (pts) with advanced hepatocellular carcinoma (HCC)
Long-term follow-up of a phase 2 study of tislelizumab (tis) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors
Pathological response to neoadjuvant tislelizumab (tis) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIa NSCLC patients (pts) in the phase 3 (Ph3) RATIONALE-315 trial
Phase (Ph) 1/2 study of sitravatinib (sitra) alone or with tislelizumab (tis) in advanced hepatocellular carcinoma (HCC) and gastric/gastroesophageal junction cancer (GC/GEJC)
Randomized, global, phase 3 study of tislelizumab (tis) + chemotherapy (chemo) vs placebo (pbo) + chemo as first-line (1l) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306
Tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): final analysis results of the RATIONALE-305 study
Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): updated results from a phase 1b/2 study
October 2023
Japan Society of Clinical Oncology (JSCO)
Japan Society of Clinical Oncology (JSCO)
October 2023 (Yokohama, Japan)
October 2023
German, Austrian, and Swiss Societies for Hematology & Medical Oncology (DGHO)
German, Austrian, and Swiss Societies for Hematology & Medical Oncology (DGHO)
October 2023 (Hamburg, Germany)
October 2023
Japanese Society of Hematology (JSH)
Japanese Society of Hematology (JSH)
October 2023 (Tokyo, Japan)
Presentations
October 2023
international workshop on CLL (iwCLL)
international workshop on CLL (iwCLL)
October 2023 (Boston, Massachusetts, USA)
Posters
A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL
Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
Abstracts
A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL
Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
September 2023
International Myeloma Society (IMS)
International Myeloma Society (IMS)
September 2023 (Athens, Greece)
September 2023
Sociedad Española de Oncología Médica (SEOM)
Sociedad Española de Oncología Médica (SEOM)
September 2023 (Barcelona, Spain)
September 2023
Polish Society of Hematology and Transfusion Medicine (PTHiT)
Polish Society of Hematology and Transfusion Medicine (PTHiT)
September 2023 (Katowice, Poland)
Presentations
Zanubrutinib demonstrated superior progression-free survival vs ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: final analysis of phase 3 ALPINE study
Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Posters
MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma
Updated safety and efficacy results of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib
Abstracts
MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma
Updated safety and efficacy results of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib
Zanubrutinib demonstrated superior progression-free survival vs ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: final analysis of phase 3 ALPINE study
Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
September 2023
World Conference on Lung Cancer (WCLC)
World Conference on Lung Cancer (WCLC)
September 2023 (Singapore)
Presentations
September 2023
Korean Society of Medical Oncology (KSMO)
Korean Society of Medical Oncology (KSMO)
September 2023 (Seoul, Korea)
Posters
Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: updated results from a phase Ib/II study
RATIONALE-305: Phase 3 study of tislelizumab plus chemotherapy versus placebo + chemotherapy as first first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma
Abstracts
Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: updated results from a phase Ib/II study
RATIONALE-305: Phase 3 study of tislelizumab plus chemotherapy versus placebo + chemotherapy as first first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma
August 2023
Asia-Pacific Gastroenterology Cancer Summit (APGCS)
Asia-Pacific Gastroenterology Cancer Summit (APGCS)
August 2023 (Singapore)
Posters
Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS)
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population
Abstracts
Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS)
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population
August 2023
International Society for Pharmacoepidemiology (ICPE)
International Society for Pharmacoepidemiology (ICPE)
August 2023 (Halifax, Nova Scotia, Canada)
August 2023
American Society of Clinical Oncology - Breakthrough (ASCO Breakthrough)
American Society of Clinical Oncology - Breakthrough (ASCO Breakthrough)
August 2023 (Yokohama, Japan)
Presentations
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC)
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population
Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): updated results from a phase Ib/II study
Posters
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC)
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population
Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): updated results from a phase Ib/II study
Abstracts
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC)
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population
Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): updated results from a phase Ib/II study
July 2023
Translational Summit on Hematologic Malignancies (DAVA Oncology Meetings)
Translational Summit on Hematologic Malignancies (DAVA Oncology Meetings)
July 2023 (Bermuda)
Posters
Bruton tyrosine kinase (BTK) protein degrader BGB-16673 is less apt to cause, and able to overcome variable BTK resistance mutations compared to other BTK inhibitors
Characterization of zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Preliminary safety and efficacy of BGB-11417, a novel Bcl-2 inhibitor, in combination with azacitidine in patients with acute myeloid leukemia
Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study
Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed or refractory follicular lymphoma: updated analysis of the ROSEWOOD study
June 2023
World Congress on Gastrointestinal Cancer (WCGI)
World Congress on Gastrointestinal Cancer (WCGI)
June 2023 (Barcelona, Spain)
June 2023
Health Technology Assessment international (HTAi)
Health Technology Assessment international (HTAi)
June 2023 (Adelaide, South Australia, Australia)
June 2023
European Association for the Study of the Liver (EASL)
European Association for the Study of the Liver (EASL)
June 2023 (Vienna, Austria)
Posters
Association of tumor response with survival in patients with unresectable hepatocellular carcinoma treated with first-line tislelizumab versus sorafenib: results from the Rationale-301 study
Impact of baseline liver function on overall survival and safety in patients with unresectable hepatocellular carcinoma treated with first-line tislelizumab: results from the rationale-301 study
Abstracts
Association of tumor response with survival in patients with unresectable hepatocellular carcinoma treated with first-line tislelizumab versus sorafenib: results from the Rationale-301 study
Impact of baseline liver function on overall survival and safety in patients with unresectable hepatocellular carcinoma treated with first-line tislelizumab: results from the rationale-301 study
June 2023
International Conference on Malignant Lymphoma (ICML)
International Conference on Malignant Lymphoma (ICML)
June 2023 (Lugano, Switzerland)
Presentations
Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma
Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Zanubrutinib vs bendamustine + rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Posters
A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL
First interim analysis of a phase 1 study of zanubrutinib + lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma
Long-term efficacy and safety of zanubrutinib in relapsed/refractory marginal zone lymphoma (R/R MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
Matching-adjusted indirect comparison (MAIC) of zanubrutinib vs ibrutinib in relapsed/refractory marginal zone lymphoma (R/R MZL)
Zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in B-cell malignancies: post hoc analysis of a large clinical trial safety database
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life
Abstracts
A meta-analytic endpoint validation of surrogates used in clinical trials evaluating the efficacy of therapies in patients with chronic lymphocytic leukemia (CLL)
A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL
First interim analysis of a phase 1 study of zanubrutinib (zanu) + lenalidomide (len) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE
Long-term efficacy and safety of zanubrutinib (ZANU) in relapsed/refractory marginal zone lymphoma (R/R MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 versus lenalidomide plus rituximab in patients with relapsed/refractory follicular or marginal zone lymphoma
Matching-adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) vs ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL)
Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) CLL/SLL: extended follow-up of the SEQUOIA study
Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in B-cell malignancies: Post hoc analysis of a large clinical trial safety database
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life
June 2023
European Hematology Association (EHA)
European Hematology Association (EHA)
June 2023 (Frankfurt, Germany)
Posters
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies
BGB-16673, a BTK degrader, overcomes on-target resistance from BTK inhibitors and presents sustainable long-term tumor regression in lymphoma xenograft models
Bruton tyrosine kinase (BTK) protein degrader BGB-16673 is less apt to cause, and able to overcome variable BTK resistance mutations compared to other BTK inhibitors
Characterization of zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Comparative efficacy of zanubrutinib versus rituximab in relapsed marginal zone lymphoma (MZL): matching-adjusted indirect comparison (MAIC)
First interim analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma
Health-relayed quality of life in patients with Waldenström macroglobulinemia (WM) treated with zanubrutinib vs ibrutinib: results from the phase 3 ASPEN trial long-term follow-up
Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
Matching-adjusted indirect comparison (MAIC) of zanubrutinib versus ibrutinib in relapsed/refractory marginal zone lymphoma (R/R MZL)
Real-world treatment patterns of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma in community oncology practices in the United States
Updated safety and efficacy results of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib
Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study
Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
Abstracts
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies
BGB-16673, a BTK degrader, overcomes on-target resistance from BTK inhibitors and presents sustainable long-term tumor regression in lymphoma xenograft models
Bruton tyrosine kinase (BTK) protein degrader BGB-16673 is less apt to cause, and able to overcome variable BTK resistance mutations compared to other BTK inhibitors (BTKi)
Characterization of zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Comparative efficacy of zanubrutinib (zanu) versus rituximab (rtx) in relapsed marginal zone lymphoma (MZL): matching-adjusted indirect comparison (MAIC)
Efficacy and safety of once daily (QD) vs twice daily (BID) zanubrutinib for patients with various B-cell malignancies: a comparative summary of clinical data and exposure-response analysis
First interim analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma
Health-related quality of life in patients (pts) with Waldenström macroglobulinemia (WM) treated with zanubrutinib (zanu) vs ibrutinib (ibr): results from the phase 3 ASPEN trial long-term follow-up
Long-term efficacy and safety of zanubrutinib (zanu) in patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma
Matching-adjusted indirect comparison (MAIC) of zanubrutinib (zanu) versus ibrutinib (ibru) in relapsed/refractory marginal zone lymphoma (R/R MZL)
Persistence with oral therapy as reflection of actual compliance for chronic lymphocytic leukemia (CLL) - a national prescribed drug and patient registered study from Sweden
Real-world treatment patterns of Bruton tyrosine kinase inhibitors (BTKi) in patients with mantle cell lymphoma (MCL) in community oncology practices in the United States (US)
The meta-analytic endpoint validation of surrogates used in clinical trials evaluating the efficacy of therapies in patients with chronic lymphocytic leukemia
Updated safety and efficacy results of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib
Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study
Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
June 2023
American Society of Clinical Oncology (ASCO)
American Society of Clinical Oncology (ASCO)
June 2023 (Chicago, Illinois, USA)
Posters
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies
A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC)
First interim analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma
Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS)
MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma
Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): the RATIONALE-301 European/North American (EU/NA) subgroup
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): updated results from a phase Ib/II study
Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed or refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Abstracts
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies
A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC)
Comparative efficacy of zanubrutinib (ZANU) versus rituximab (RTX) in relapsed marginal zone lymphoma (MZL): matching-adjusted indirect comparison (MAIC)
First interim analysis of a phase 1 study of zanubrutinib (zanu) plus lenalidomide (len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS)
MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma
Matching-adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL)
Real-world treatment patterns of Bruton tyrosine kinase inhibitors (BTKi) in patients with mantle cell lymphoma (MCL) in community oncology practices in the United States (US)
Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: zanidatamab in previously- treated HER2-amplified biliary tract cancer (BTC)
Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): the RATIONALE-301 European/North American (EU/NA) subgroup
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): updated results from a Phase Ib/II study
Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
May 2023
International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
May 2023 (Boston, MA, United States)
April 2023
British Society for Haematology (BSH)
British Society for Haematology (BSH)
April 2023 (Birmingham, England)
Presentations
Preliminary safety and efficacy of BGB-11417 (novel Bcl-2 inhibitor) in combination with azacitidine in AML
Rate of cardiac disorders in patients with B-cell malignancies who undergo treatment with zanubrutinib
Zanubrutinib demonstrates superior progression-free survival vs ibrutinib for relapsed/refractory CLL/SLL: ALPINE final analysis
Zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MZL): final analysis of MAGNOLIA (BGB-3111-214)
Posters
BGB-11417 (Bcl-2 inhibitor) monotherapy or combination therapy with zanubrutinib in non-Hodgkin lymphoma or Waldenström macroglobulinemia patients
BGB-11417 (Bcl-2 inhibitor) monotherapy or combination with zanubrutinib in CLL/SLL patients: preliminary phase 1 data
Preliminary safety of Bcl-2 inhibitor BGB-11417 in relapsed/refractory multiple myeloma harboring t(11,14): phase 1b/2 Study
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Abstracts
BGB-11417 (Bcl-2 inhibitor) monotherapy or combination therapy with zanubrutinib in non-Hodgkin lymphoma or Waldenström macroglobulinemia patients
BGB-11417 (Bcl-2 inhibitor) monotherapy or combination with zanubrutinib in CLL/SLL patients: preliminary phase 1 data
Preliminary safety and efficacy of BGB-11417 (novel Bcl-2 inhibitor) in combination with azacitidine in AML
Preliminary safety of Bcl-2 inhibitor BGB-11417 in relapsed/refractory multiple myeloma harboring t(11,14): phase 1b/2 Study
Rate of cardiac disorders in patients with B-cell malignancies who undergo treatment with zanubrutinib
Zanubrutinib demonstrates superior progression-free survival vs ibrutinib for relapsed/refractory CLL/SLL: ALPINE final analysis
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MZL): final analysis of MAGNOLIA (BGB-3111-214)
April 2023
American Association for Cancer Research (AACR)
American Association for Cancer Research (AACR)
April 2023 (Orlando, Florida, USA)
Presentations
A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors
Safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors
Posters
Association of tumor mutational burden (TMB) and clinical outcomes with tislelizumab versus chemotherapy in esophageal squamous cell carcinoma (ESCC) from RATIONALE-302.
BGB-24714, a novel oral IAP antagonist, displayed significant anti-tumor activities in preclinical models as a monotherapy and in combination with paclitaxel
Longitudinal ctDNA levels and clinical outcomes of first-line (1L) tislelizumab (TIS) + chemotherapy (chemo) treatment for advanced non-small cell lung cancer (NSCLC) in the RATIONALE-304 and 307 studies
Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis
Abstracts
A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors
Association of tumor mutational burden (TMB) and clinical outcomes with tislelizumab versus chemotherapy in esophageal squamous cell carcinoma (ESCC) from RATIONALE-302.
BGB-24714, a novel oral IAP antagonist, displayed significant anti-tumor activities in preclinical models as a monotherapy and in combination with paclitaxel
Longitudinal ctDNA levels and clinical outcomes of first-line (1L) tislelizumab (TIS) + chemotherapy (chemo) treatment for advanced non-small cell lung cancer (NSCLC) in the RATIONALE-304 and 307 studies
Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis
Safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors
March 2023
French Society of Hematology (SFH)
French Society of Hematology (SFH)
March 2023 (Paris, France)
Presentations
Posters
A phase 1 study with the novel B-cell lymphoma 2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with non-Hodgkin lymphoma or Waldenström
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
Abstracts
A phase 1 study with the novel B-cell lymphoma (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data
A phase 1 study with the novel B-cell lymphoma (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with non-Hodgkin's lymphoma or Waldenström macroglobulinemia
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia
Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of MAGNOLIA (BGB-3111-214) trial
Zanubrutinib demonstrates superior progression-free survival versus ibrutinib for relapsed/refractory CLL/SLL: ALPINE final analysis
March 2023
Hematology/Oncology Pharmacy Association (HOPA)
Hematology/Oncology Pharmacy Association (HOPA)
March 2023 (Phoenix, Arizona, USA)
Posters
Rate of atrial fibrillation in patients with B-cell malignancies who undergo treatment with zanubrutinib
Real world evidence of impact of atrial fibrillation on clinical and economic outcomes in patients with chronic lymphocytic leukemia
Real-world treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma
Real-world treatment patterns and economic burden of patients with marginal zone lymphoma
Zanubrutinib demonstrates superior progression-free survival compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from final analysis of ALPINE randomized phase 3 study
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
March 2023
Whistler Summit on Hematologic Malignancies (DAVA Oncology Meetings)
Whistler Summit on Hematologic Malignancies (DAVA Oncology Meetings)
March 2023 (Whistler, British Columbia, Canada)
Posters
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data
Preliminary safety and efficacy of BGB-11417, a novel Bcl-2 inhibitor, in combination with azacitidine in patients with acute myeloid leukemia
Rate of atrial fibrillation in patients with B-cell malignancies who undergo treatment with zanubrutinib
Zanubrutinib demonstrates superior progression-free survival compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from final analysis of ALPINE randomized phase 3 study
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
March 2023
American Society for Clinical Pharmacology & Therapeutics (ASCPT)
American Society for Clinical Pharmacology & Therapeutics (ASCPT)
March 2023 (Atlanta, Georgia, USA)
March 2023
Francophone Days of Hepato-gastroenterology and Digestive Oncology (JFHOD)
Francophone Days of Hepato-gastroenterology and Digestive Oncology (JFHOD)
March 2023 (Paris, France)
March 2023
Japanese Society of Medical Oncology (JSMO)
Japanese Society of Medical Oncology (JSMO)
March 2023 (Fukuoka, Japan)
February 2023
International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma (ICHM )
International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma (ICHM )
February 2023 (Miami Beach, Florida, USA)
Posters
Preliminary safety of Bcl-2 inhibitor BGB-11417 in relapsed/refractory multiple myeloma harboring t(11,14): phase 1b/2 study
Rate of cardiac disorders in patients with B-cell malignancies who undergo treatment with zanubrutinib
Zanubrutinib in patients with B-cell malignancies intolerant to acalabrutinib
Abstracts
Preliminary safety of Bcl-2 inhibitor BGB-11417 in relapsed/refractory multiple myeloma harboring t(11,14): phase 1b/2 study
Rate of cardiac disorders in patients (pts) with B-cell malignancies who undergo treatment with zanubrutinib (zanu)
Zanubrutinib (zanu) in patients (pts) with B-cell malignancies intolerant to acalabrutinib (acala)
February 2023
American Society of Clinical Oncology - Genitourinary Cancers Symposium (ASCO-GU)
American Society of Clinical Oncology - Genitourinary Cancers Symposium (ASCO-GU)
February 2023 (San Francisco, California, USA)
February 2023
Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem)
Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem)
February 2023 (Orlando, Florida, USA)
January 2023
American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (ASCO-GI)
American Society of Clinical Oncology - Gastrointestinal Cancers Symposium (ASCO-GI)
January 2023 (San Francisco, California, USA)
Presentations
RATIONALE 305: phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC)
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population
Posters
Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): non-Asia subgroup
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population
Abstracts
RATIONALE 305: phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC)
Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): non-Asia subgroup
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population
December 2022
American Society of Hematology (ASH)
American Society of Hematology (ASH)
December 2022 (New Orleans, Louisiana, USA)
Presentations
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data
Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
Zanubrutinib demonstrates superior progression-free surivival compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from final analysis of ALPINE randomized phase 3 study
Posters
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies: preliminary data
A phase 1 study with the novel B-cell lymphoma 2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with non-Hodgkin lymphoma or Waldenström macroglobulinemia: preliminary data
Biomarker analysis of zanubrutinib and tislelizumab combination therapy in patients with relapsed/refractory B-cell malignancies
Efficacy and safety of zanubrutinib in Japanese patients with mature B-cell malignancies
Genomic characterization of patients in a phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients with relapsed/refractory B-cell malignancies
Long-term outcomes of second-line vs later-line zanubrutinib treatment in patients with relaped/refractory MCL: an updated pooled analysis
Preliminary safety and efficacy of BGB-11417, a novel Bcl-2 inhibitor, in combination with azacitidine in patients with acute myeloid leukemia
Preliminary safety and efficacy of zanubrutinib in combination with lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma
Preliminary safety of a Bcl-2 inhibitor, BGB-11417, in patients with relapsed/refractory multiple myeloma harboring t(11,14): a nonrandomized, open-label, phase 1b/2 study
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Abstracts
A phase 1 study evaluating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies: preliminary data
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with non-Hodgkin lymphoma or Waldenström macroglobulinemia (WM): preliminary data
A phase 1 with the novel B-cell lymphoma 2 (Bcl-1) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with CLL/SLL: preliminary data
Biomarker analysis of zanubrutinib and tislelizumab combination therapy in patients with relapsed/refractory B-cell malignancies
Development of hypertension and atrial fibrillation following diagnosis of B-cell malignancies - a retrospective analysis of US MarketScan insurance claims database
Efficacy and safety of zanubrutinib in Japanese patients with mature B-cell malignancies
Genomic characterization of patients in a phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients with relapsed/refractory B-cell malignancies
Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
Long-term outcomes of second-line vs later-line zanubrutinib treatment in patients with relapsed/refractory MCL: an updated pooled analysis
Preliminary safety and efficacy of BGB-11417, a novel Bcl-2 inhibitor, in combination with azacitidine in patients with acute myeloid leukemia (AML)
Preliminary safety and efficacy of zanubrutinib in combination with lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma
Preliminary safety of a Bcl-2 inhibitor, BGB-11417, in patients with relapsed/refractory multiple myeloma harboring t(11,14): a non-randomized, open-label, phase 1b/2 study
Real-world evidence (RWE) studies supported hematologic oncology United States Food and Drug Administration (US FDA) approval: what do they look like?
Zanubrutinib demonstrates superior progression-free survival (PFS) compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): results from final analysis of ALPINE randomized phase 3 study
Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies
December 2022
European Society of Medical Oncology Immuno-Oncology (ESMO-IO)
European Society of Medical Oncology Immuno-Oncology (ESMO-IO)
December 2022 (Geneva, Switzerland)
Posters
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with checkpoint inhibitor-experienced advanced NSCLC
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with extensive-stage small cell lung cancer
Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: A single-arm, multicenter, phase II trial
Randomized phase 3 study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced nonsquamous non-small cell lung cancer: RATIONALE-304 updated analysis
Randomized phase 3 study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer: RATIONALE-307 updated analysis
Abstracts
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with checkpoint inhibitor-experienced advanced non-small cell lung cancer
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with extensive-stage small cell lung cancer
Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: A single-arm, multicenter, phase II trial
Randomized phase 3 study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-squamous non-small cell lung cancer : RATIONALE-304 updated analysis
Randomized phase 3 study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer : RATIONALE-307 updated analysis
December 2022
European Society for Medical Oncology-Asia (ESMO-Asia)
European Society for Medical Oncology-Asia (ESMO-Asia)
December 2022 (Singapore)
Presentations
Patterns of treatment and outcomes in CLL patients in Australia: an analysis of the population-wide pharmaceutical benefits scheme dataset
Patterns of treatment and outcomes in MCL patients in Australia: an analysis of the population-wide pharmaceutical benefits scheme dataset
RATIONALE-309: effects of tislelizumab on health-related quality of life (HRQoL) in patients with recurrent or metastatic nasopharyngeal cancer (R/M NPC)
Randomized, global, phase 3 study of tislelizumab plus chemotherapy vs chemotherapy as first-line therapy for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): Asia subgroup
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: the RATIONALE-301 Chinese subpopulation analysis
Abstracts
Patterns of treatment and outcomes in CLL patients in Australia: an analysis of the population-wide pharmaceutical benefits scheme dataset
Patterns of treatment and outcomes in MCL patients in Australia: an analysis of the population-wide pharmaceutical benefits scheme dataset
RATIONALE-302: tislelizumab vs chemotherapy as second-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC): impact on health-related quality of life (HRQoL) in Asian patients
RATIONALE-309: effects of tislelizumab on health-related quality of life (HRQoL) in patients with recurrent or metastatic nasopharyngeal cancer (R/M NPC)
Randomized, global, phase 3 study of tislelizumab (TIS) + chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup
Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): the RATIONALE-301 Chinese subpopulation analysis
November 2022
German Cancer Congress (DKK)
German Cancer Congress (DKK)
November 2022 (Berlin, Germany)
November 2022
Korean Association for Lung Cancer (KALC)
Korean Association for Lung Cancer (KALC)
November 2022 (Seoul, South Korea)
Presentations
November 2022
Society for Immunotherapy of Cancer (SITC)
Society for Immunotherapy of Cancer (SITC)
November 2022 (Boston, Massachusetts, USA)
Posters
DKN-01 and tislelizumab as a second-line investigational therapy in advanced DKK1-high gastroesophageal adenocarcinoma : DisTinGuish trial
Peripheral pharmacodynamic effects of ociperlimab in combination with tislelizumab in patients with advanced solid tumors: AdvanTIG-105 Phase 1 dose-escalation study
Abstracts
DKN-01 and tislelizumab as a second-line investigational therapy in advanced DKK1-high gastroesophageal adenocarcinoma : DisTinGuish trial
Peripheral pharmacodynamic effects of ociperlimab in combination with tislelizumab in patients with advanced solid tumors: AdvanTIG-105 Phase 1 dose-escalation study
November 2022
Portuguese Society of Hematology (SPH)
Portuguese Society of Hematology (SPH)
November 2022 (Tróia, Portugal)
Abstracts
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
Long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM)
November 2022
International Society for Pharmacoeconomics and Outcomes Research - Europe (ISPOR-EU)
International Society for Pharmacoeconomics and Outcomes Research - Europe (ISPOR-EU)
November 2022 (Vienna, Austria)
Posters
Budget impact analysis of zanubrutinib for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma in the United States
Budget impact analysis of zanubrutinib for treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma in the United States
Lessons learned from successful real-world evidence (RWE) studies supporting regulatory drug approvals
Zanubrutinib versus ibrutinib to treat adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a cost per responder model from a payer perspective in the United States
Abstracts
Budget impact analysis of zanubrutinib for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma in the United States
Budget impact of zanubrutinib for treatment of relapsed or refractory chronic lymphocytic leukemia in the United States
Lessons learned from successful real-world evidence (RWE) studies supporting regulatory drug approvals
Zanubrutinib versus ibrutinib to treat adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a cost per responder model from a payer perspective in the United States
November 2022
Chinese Society of Clinical Oncology (CSCO)
Chinese Society of Clinical Oncology (CSCO)
November 2022 (China)
Presentations
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with metastatic squamous and nonsquamous non-small cell lung cancer
AdvantTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic non-small cell lung cancer
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia
Tislelizumab versus docetaxel as second- or third-line therapy in previously treated patients with locally advanced non-small cell lung cancer: asian versus non-asian subgroup analysis of the RATIONALE-303 study
Posters
RATIONALE-304: the association of tumor mutational burden with clinical outcomes of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced nonsquamous non-small cell lung cancer
RATIONALE-304: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for nonsquamous nsclc in patients aged 65-75 years
HERIZON-GEA-01: a phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive (her2+) advanced/metastatic gastroesophageal adenocarcinoma
HERIZON-GEA-01: a phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive advanced or metastatic gastroesophageal adenocarcinoma
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma
Tislelizumab versus docetaxel in patients with previously treated advanced nonsquamous non-small cell lung cancer: subanalysis from the RATIONALE-303 phase 3 randomized clinical study
Tislelizumab versus docetaxel in previously treated advanced non-small cell lung cancer: final analysis of RATIONALE-303
Abstracts
Time to response and depth of response in non-squamous non-small cell lung cancer patients treated with tislelizumab plus chemotherapy as first line therapy: an exploratory analysis of RATIONALE-304
Tislelizumab versus docetaxel as second- or third-line therapy in previously treated patients with locally advanced non-small cell lung cancer: asian versus non-asian subgroup analysis of the RATIONALE-303 study
RATIONALE-304: tislelizumab plus chemotherapy versus chemotherapy alone as first line treatment for nonsquamous non-small cell lung cancer in patients aged 65-75 years
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma
A matching-adjusted indirect comparison of tislelizumab versus camrelizumab as second-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM)
AdvanTIG-105: a phase 1 dose-verification study of ociperlimab in combination with tislelizumab in advanced solid tumors in Chinese patients
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with metastatic squamous and nonsquamous non-small cell lung cancer
AdvantTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic non-small cell lung cancer
HERIZON-GEA-01: a phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive advanced or metastatic gastroesophageal adenocarcinoma
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients (pts) with acute myeloid leukemia (AML)
Rationale-304: the association of tumor mutational burden with clinical outcomes of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced nonsquamous non-small cell lung cancer
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine plus rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic gastric cancer or gastroesophageal junction cancer
The effects of tislelizumab treatment on the health-related quality of life of non-small cell lung cancer patients who progressed on a prior platinum-containing regimen
Tislelizumab versus docetaxel in patients with previously treated advanced nonsquamous non-small cell lung cancer: subanalysis from the RATIONALE-303 phase 3 randomized clinical study
Tislelizumab versus docetaxel in patients with previously treated advanced squamous non-small cell lung cancer: sub-analysis from phase 3 RATIONALE-303 randomized clinical study
Tislelizumab versus docetaxel in previously treated advanced non-small cell lung cancer: final analysis of RATIONALE-303
Zanubrutinib plus obinutuzumab (ZO) vs obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial
November 2022
Clinical Oncology Society of Australia (COSA)
Clinical Oncology Society of Australia (COSA)
November 2022 (Brisbane, Australia)
Posters
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, nonsquamous non-small cell lung cancer; SAFFRON-103
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, squamous non-small cell lung cancer; SAFFRON-103
Abstracts
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, nonsquamous non-small cell lung cancer
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, squamous non-small cell lung cancer
October 2022
International Workshop on Waldenström's Macroglobulinemia (IWWM)
International Workshop on Waldenström's Macroglobulinemia (IWWM)
October 2022 (Madrid, Spain)
Presentations
ASPEN biomarker analysis: response to BTK inhibitor treatment in patients with Waldenström macroglobulinemia harboring CXCR4, TP53, and TERT mutations
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
Extended follow-up of a phase 2 trial of the Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in Chinese patients with relapsed/refractory Waldenström macroglobulinemia
Zanubrutinib in patients intolerant to ibrutinib/acalabrutinib
Zanubrutinib or the treatment of patients with Waldenström macroglobulinemia: 4 years of follow-up
Abstracts
ASPEN biomarker analysis: response to Bruton Tyrosine Kinase Inhibitor (BTKi) treatment in patients with Waldenström macroglobulinemia (WM) harboring CXCR4, TP53, and TERT mutations
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM)
Extended follow-up of a phase 2 trial of the Bruton tyrosine-kinase inhibitor zanubrutinib (BGB-3111) in Chinese patients with relapsed/refractory Waldenström macroglobulinemia
Preliminary results for patients with Waldenström macroglobulinemia from the phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib
Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia
October 2022
Japan Society of Clinical Oncology (JSCO)
Japan Society of Clinical Oncology (JSCO)
October 2022 (Kobe, Japan)
October 2022
Lymphoma, Leukemia & Myeloma (LLM)
Lymphoma, Leukemia & Myeloma (LLM)
October 2022 (New York, New York, USA)
October 2022
Japanese Society of Hematology (JSH)
Japanese Society of Hematology (JSH)
October 2022 (Fukuoka, Japan)
October 2022
German, Austrian, and Swiss Societies for Hematology & Medical Oncology (DGHO)
German, Austrian, and Swiss Societies for Hematology & Medical Oncology (DGHO)
October 2022 (Vienna, Austria)
Presentations
A phase 1 study with the novel Bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC)
Posters
Randomized, phase 3 study of second-line treatment vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302) in the overall population and Europe/North America subgroup
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life
Abstracts
A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with B-cell malignancies: preliminary data
RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC)
Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302) in the overall population and Europe/North America subgroup
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab (BR) in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQOL)
October 2022
Spanish Society of Hematology and Hemotherapy (SEHH)
Spanish Society of Hematology and Hemotherapy (SEHH)
October 2022 (Barcelona, Spain)
Presentations
A phase 1 study with the novel Bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM)
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory CLL/SLL
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (Bcl-2) inhibitor, in patients with acute myeloid leukemia (AML)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab in patients with treatment-naïve CLL/SLL
Posters
Abstracts
A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM)
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL)
Impact of atrial fibrillation in onco-hematological patients in Europe: a targeted literature review
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia (AML)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab (BR) in patients with treatment-naïve chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL)
September 2022
Society of Hematologic Oncology (SOHO)
Society of Hematologic Oncology (SOHO)
September 2022 (Houston, Texas, USA)
Posters
A phase 1 study with the novel Bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs. ibrutinib in patients with Waldenström macroglobulinemia
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma
Abstracts
A phase 1 study with the novel B-cell lymphoma 2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
September 2022
Italian Society of Hematology (SIE)
Italian Society of Hematology (SIE)
September 2022 (Rome, Italy)
Presentations
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Zanubrutinib in older patients with relapsed/refractory marginal zone lymphoma: subgroup analysis of the MAGNOLIA study
Zanubrutinib plus obtinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma: primary analysis of the phase 2 randomized ROSEWOOD trial
Posters
A phase 2 study with the novel B-cell lymphoma (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
Abstracts
A phase 2 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients (pts) with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM)
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Zanubrutinib (zanu) in older patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): subgroup analysis of the MAGNOLIA study
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial
September 2022
New Zealand Society for Oncology (NZSO)
New Zealand Society for Oncology (NZSO)
September 2022 (Christchurch, New Zealand)
September 2022
BLOOD Annual Scientific Meeting (BLOOD)
BLOOD Annual Scientific Meeting (BLOOD)
September 2022 (Sydney, Australia)
Presentations
A phase 1 study with the novel BCL2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory CLL/SLL
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients with AML
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naive CLL/SLL
Posters
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia
Population-wide patterns of care in CLL in Australia: an analysis of the pharmaceutical benefits scheme data set
Population-wide patterns of care in mantle cell lymphoma in Australia: an analysis of the pharmaceutical benefits scheme data set
Abstracts
A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM)
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Population-wide patterns of care in chronic lymphocytic leukemia (CLL) in Australia: an analysis of the pharmaceutical benefits scheme (PBS) dataset
Population-wide patterns of care in mantle cell lymphoma (MCL) in Australia: an analysis of the pharmaceutical benefits scheme (PBS) dataset
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia (AML)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
September 2022
European Society for Medical Oncology (ESMO)
European Society for Medical Oncology (ESMO)
September 2022 (Paris, France)
Posters
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab + tislelizumab with chemotherapy in patients with metastatic squamous and nonsquamous non-small cell lung cancer
AdvanTIG-205: phase 2 trial of ociperlimab plus tislelizumab plus chemotherapy in first-line treatment of patients with locally advanced, unresectable, or metastatic non-small cell lung cancer
DKN-01 and tislelizumab + chemotherapy as first-line (1L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
SAFFRON-301: a phase 3 study of tislelizumab with sitravatinib versus chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer previously treated with platinum-based chemotherapy and an anti-PD-1/PD-L1 antibody
Tislelizumab versus docetaxel as second- or third-line therapy in previously treated patients with advanced non-small cell lung cancer (NSCLC): Asian and non-Asian subgroup analysis of the RATIONALE-303 study
Abstracts
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamous (non-sq) non-small cell lung cancer (NSCLC)
AdvanTIG-205: phase 2 trial of ociperlimab (OCI) + tislelizumab (TIS) + chemotherapy (chemo) in first line (1L) treatment of patients (pts) with locally advanced (LA), unresectable, or metastatic non-small cell lung cancer (mNSCLC)
Final analysis of RATIONALE-301: randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
Phase 3 study of tislelizumab (TIS) with sitravatinib versus chemotherapy (chemo) in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with chemo and an anti-programmed cell death protein 1/ligand 1 (PD-[L]1) antibody
Tislelizumab (TIS) versus docetaxel (TAX) as second- or third-line therapy in previously treated patients (pts) with locally advanced non-small cell lung cancer (NSCLC): Asian versus non-Asian subgroup analysis of the RATIONALE-303 study
September 2022
Polish Society of Hematology and Transfusion Medicine (PTHiT)
Polish Society of Hematology and Transfusion Medicine (PTHiT)
September 2022 (Bydgoszcz, Poland)
Presentations
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naive CLL/SLL
Abstracts
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
September 2022
Korean Society of Medical Oncology (KSMO)
Korean Society of Medical Oncology (KSMO)
September 2022 (Seoul, South Korea)
Presentations
HERIZON-GEA-01: a phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (GEA)
Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup
Abstracts
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic NSCLC
HERIZON-GEA-01: phase 3 study of zanidatamab (ZANI) + chemotherapy (chemo) ± tislelizumab (TIS) in first-line (1L) human epidermal growth factor receptor 2 positive (HER2+) locally advanced (LA)/metastatic gastroesophageal adenocarcinoma (GEA)
Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup
August 2022
World Congress on Lung Cancer (WCLC)
World Congress on Lung Cancer (WCLC)
August 2022 (Vienna, Austria)
Posters
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic NSCLC
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, nonsquamous non-small cell lung cancer; SAFFRON-103
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, squamous non-small cell lung cancer; SAFFRON-103
Tislelizumab versus docetaxel in previously treated advanced non-small cell lung cancer (NSCLC): final analysis of RATIONALE-303
Abstracts
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic NSCLC
Safety and efficacy of sitravatinib + tislelizumab in patients with PD-L1+, locally advanced/metastatic, non-squamous NSCLC
Safety and efficacy of sitravatinib + tislelizumab in patients with PD-L1+, locally advanced/metastatic, squamous NSCLC
Tislelizumab versus docetaxel in previously treated advanced non-small cell lung cancer: final analysis of RATIONALE-303
July 2022
Pan Pacific Lymphoma Conference (PPLC)
Pan Pacific Lymphoma Conference (PPLC)
July 2022 (Kauai, Hawaii)
Posters
ASPEN: long‑term follow‑up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma
Zanubrutinib in 13 acalabrutinib‑intolerant patients with B‑Cell malignancies
Abstracts
ASPEN: long‑term follow‑up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib (ZANU) versus bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Zanubrutinib in 13 acalabrutinib‑intolerant patients (pts) with B‑cell malignancies
June 2022
World Congress on Gastrointestinal Cancer (WCGI)
World Congress on Gastrointestinal Cancer (WCGI)
June 2022 (Barcelona, Spain)
Posters
Subgroup analysis of the number of prior lines of systemic therapy and clinical outcomes associated with tislelizumab in patients with previously treated advanced hepatocellular carcinoma
Tislelizumab monotherapy for patients with previously treated advanced hepatocellular carcinoma: RATIONALE-208 Chinese subpopulation
Abstracts
RATIONALE-306: randomized, multi-regional, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for locally advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC)
Subgroup analysis of the number of prior lines of systemic therapy and clinical outcomes associated with tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC)
Tislelizumab monotherapy for patients with previously treated advanced hepatocellular carcinoma (HCC): RATIONALE-208 Chinese subpopulation
June 2022
Asian Oncology Society (AOS)
Asian Oncology Society (AOS)
June 2022 (Seoul, Korea)
June 2022
European Hematology Association (EHA)
European Hematology Association (EHA)
June 2022 (Vienna, Austria)
Posters
A phase 1 first‑In‑human study of BGB‑16673, a Bruton tyrosine kinase protein degrader, in patients with B‑cell malignancies (trial in progress)
A phase 1 study with the novel BCL2 Inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long‑term follow‑up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
Health-related quality of life outcomes associated with zanubrutinib vs ibrutinib monotherapy in patients with relapsed/refractory (RR) CLL/SLL: results from the randomized phase 3 ALPINE trial
View Summary of Poster in Plain Language
Patient-reported outcomes from a phase 3 randomized study of zanubrutinib vs bendamustine plus rituximab (BR) in patients with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
View Summary of Poster in Plain Language
Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme data set
Preliminary safety and efficacy of BGB‑11417, a potent and selective B‑cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia
Real world evidence of impact of atrial fibrillation on clinical and economic outcomes in patients with chronic lymphocytic leukemia
Real-world treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma
Real-world treatment patterns and economic burden of patients with marginal zone lymphoma
Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia
Tislelizumab, a PD‑1 inhibitor for relapsed/refractory mature (NK)/T‑cell neoplasms: results from a phase 2 study
Zanubrutinib in older patients with relapsed/refractory marginal zone lymphoma (MZL): subgroup analysis of the Magnolia study
Abstracts
A phase 1 first in-human study of BGB-16673, a Bruton tyrosine kinase protein degrader, in patients (pts) with B-cell malignancies (trial in progress)
A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with B-cell malignancies: preliminary data
Efficacy of first-line treatment for chronic lymphocytic leukemia: a bayesian network meta-analysis
Health-related quality of life outcomes associated with zanubrutinib vs ibrutinib monotherapy in patients with relapsed/refractory (RR) CLL/SLL: results from the randomized phase 3 ALPINE trial
Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia
Patient-reported outcomes from a phase 3 randomized study of zanubrutinib versus bendamustine plus rituximab (BR) in patients with treatment-naïve (TN) CLL/SLL
Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme dataset
Population-wide patterns of care in mantle cell lymphoma in Australia: an analysis of the pharmaceutical benefits scheme dataset
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients (pts) with acute myeloid leukemia (AML)
Real world evidence of impact of atrial fibrillation on clinical and economic outcomes in patients with chronic lymphocytic leukemia
Real-world treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma
Real-world treatment patterns and economic burden of patients with marginal zone lymphoma
Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia
Treatment persistence and adherence to ibrutinib in patients with Waldenstrӧm macroglobulinemia: a German claims data analysis
Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies